Experienced in Irregular Sleep-Wake Syndrome

Dr. Michael J. Oliver

Internal Medicine
Mrs Physical Therapy
4538 Peach St, 
Erie, PA 
Experienced in Irregular Sleep-Wake Syndrome
Mrs Physical Therapy
4538 Peach St, 
Erie, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michael Oliver is a primary care provider, practicing in Internal Medicine in Erie, Pennsylvania. Dr. Oliver is rated as an Experienced provider by MediFind in the treatment of Irregular Sleep-Wake Syndrome. His top areas of expertise are Coronary Heart Disease, Acute Kidney Failure, Smoldering Multiple Myeloma, and Multiple Myeloma.

His clinical research consists of co-authoring 2 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in PA
Hospital Affiliations
Heritage Valley Beaver
Heritage Valley Sewickley
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Golden Rule
  • INSURANCE PLAN
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
TeamCare
  • OTHER COMMERCIAL
The Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

MRS PHYSICAL THERAPY
4538 Peach St, Erie, PA 16509
Other Locations
HERITAGE VALLEY MULTISPECIALTY GROUP INC
500 Sharon Rd, Beaver, PA 15009
HERITAGE VALLEY MULTISPECIALTY GROUP INC
1 Peartree Way, Beaver, PA 15009

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 3
A 28-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center, Study in Recombinant Human Erythropoietin (rhEPO) naïve Non-dialysis Participants With Anemia Associated With Chronic Kidney Disease to Evaluate the Efficacy, Safety and Effects on Quality of Life of Daprodustat Compared to Placebo
A 28-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center, Study in Recombinant Human Erythropoietin (rhEPO) naïve Non-dialysis Participants With Anemia Associated With Chronic Kidney Disease to Evaluate the Efficacy, Safety and Effects on Quality of Life of Daprodustat Compared to Placebo
Enrollment Status: Completed
Publish Date: April 02, 2024
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)
Enrollment Status: Completed
Publish Date: November 02, 2023
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Lispro, Insulin Glargine
Study Phase: Phase 3
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo and Dulaglutide in Participants With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drugs: LY3437943, Dulaglutide
Study Phase: Phase 2
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
A Phase 2, Parallel, Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Insulin-Naïve Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: November 02, 2022
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 2
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Semaglutide
Study Phase: Phase 3
A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes
Enrollment Status: Completed
Publish Date: January 19, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: June 12, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 11 Less Clinical Trials

2 Total Publications

The roles of repetitive negative thinking and perfectionism in explaining the relationship between sleep onset difficulties and depressed mood in adolescents.
The roles of repetitive negative thinking and perfectionism in explaining the relationship between sleep onset difficulties and depressed mood in adolescents.
Journal: Sleep health
Published: March 28, 2019
Similar Doctors
Charles P. Cole
Experienced in Irregular Sleep-Wake Syndrome
Dr. Charles P. Cole
Internal Medicine
Experienced in Irregular Sleep-Wake Syndrome
Dr. Charles P. Cole
Internal Medicine

Northwest Physicians Associates, P.C.

1012 Water Street, 
Meadville, PA 
 (31.3 miles away)
814-333-4714
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Charles Cole is a primary care provider, practicing in Internal Medicine in Meadville, Pennsylvania. Dr. Cole is rated as an Advanced provider by MediFind in the treatment of Irregular Sleep-Wake Syndrome. His top areas of expertise are Hospital-Acquired Pneumonia, Atypical Pneumonia, Pneumonia, and Folate Deficiency.

Experienced in Irregular Sleep-Wake Syndrome
Dr. Juan A. Solis
Geriatrics | Internal Medicine
Experienced in Irregular Sleep-Wake Syndrome
Dr. Juan A. Solis
Geriatrics | Internal Medicine

University Primary Care Practices Inc

158 W Main Rd, 
Conneaut, OH 
 (27.6 miles away)
Languages Spoken:
English, Filipino
See accepted insurances
Accepting New Patients

Juan Solis is a primary care provider, practicing in Geriatrics and Internal Medicine in Conneaut, Ohio. Dr. Solis is rated as an Advanced provider by MediFind in the treatment of Irregular Sleep-Wake Syndrome. His top areas of expertise are Infant Hyperglycemia, Type 2 Diabetes (T2D), High Cholesterol, and Familial Combined Hyperlipidemia. Dr. Solis is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Oliver's expertise for a condition
ConditionClose
      View All 26 Advanced Conditions
      View All 146 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile